4-phenylbutyric acid has been researched along with Nerve Degeneration in 3 studies
4-phenylbutyric acid: RN refers to the parent cpd
4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.
Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berthier, A | 1 |
| Payá, M | 1 |
| García-Cabrero, AM | 1 |
| Ballester, MI | 1 |
| Heredia, M | 1 |
| Serratosa, JM | 1 |
| Sánchez, MP | 1 |
| Sanz, P | 1 |
| Ono, K | 1 |
| Ikemoto, M | 1 |
| Kawarabayashi, T | 1 |
| Ikeda, M | 1 |
| Nishinakagawa, T | 1 |
| Hosokawa, M | 1 |
| Shoji, M | 1 |
| Takahashi, M | 1 |
| Nakashima, M | 1 |
| Kubota, K | 1 |
| Niinuma, Y | 1 |
| Kaneko, M | 1 |
| Okuma, Y | 1 |
| Sugai, M | 1 |
| Omura, T | 1 |
| Uesugi, M | 1 |
| Uehara, T | 1 |
| Hosoi, T | 1 |
| Nomura, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy[NCT04937062] | Early Phase 1 | 50 participants (Anticipated) | Interventional | 2021-03-01 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for 4-phenylbutyric acid and Nerve Degeneration
| Article | Year |
|---|---|
Pharmacological Interventions to Ameliorate Neuropathological Symptoms in a Mouse Model of Lafora Disease.
Topics: Animals; Brain; Disease Models, Animal; Fluorescent Antibody Technique; Gliosis; Glucans; Hippocampu | 2016 |
A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice.
Topics: alpha-Synuclein; Animals; Blotting, Western; Brain; Dopamine; Humans; Immunohistochemistry; Mice; Mi | 2009 |
Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Endoplasmic Reticulum; Humans; Inclusion Bodies | 2006 |